INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 36 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $129,000 | -93.6% | 186,000 | -93.3% | 0.00% | -100.0% |
| Q2 2020 | $2,005,000 | -70.4% | 2,768,000 | -45.6% | 0.00% | -50.0% |
| Q4 2019 | $6,773,000 | +30.3% | 5,088,000 | -11.7% | 0.00% | +33.3% |
| Q3 2019 | $5,198,000 | +38.1% | 5,763,000 | +52.1% | 0.00% | +50.0% |
| Q2 2019 | $3,765,000 | – | 3,790,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 27,943,000 | $20,241,000 | 1.72% |
| Worth Venture Partners, LLC | 1,569,000 | $1,134,000 | 0.56% |
| Context Capital Management, LLC | 1,985,000 | $1,424,000 | 0.55% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 16,703,000 | $12,060,000 | 0.28% |
| CSS LLC/IL | 6,825,000 | $4,985,000 | 0.28% |
| SILVERBACK ASSET MANAGEMENT LLC | 1,500,000 | $1,095,000 | 0.27% |
| Polar Asset Management Partners Inc. | 20,000,000 | $14,452,000 | 0.24% |
| Senvest Management, LLC | 5,000,000 | $3,621,000 | 0.23% |
| FARALLON CAPITAL MANAGEMENT LLC | 25,500,000 | $18,998,000 | 0.15% |
| LINDEN ADVISORS LP | 12,755,000 | $9,258,000 | 0.15% |